Clinical Characteristics of Multiple Sclerosis in African-Americans
Purpose of Review
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that affects nearly 1 million people in the USA and has the potential to profoundly affect physical ability and income potential at a young age. Since a landmark paper was published in 2014, few studies have looked at differences in MS disease characteristics between African-American and Caucasian patients.
African-American patients often have a more severe MS disease course, as well as biomarker data which can portend a worse prognosis. While the sample sizes are usually quite small, subgroup analyses of African-American patients have been performed to evaluate efficacy of disease-modifying treatments as compared with the entire study population, made up of primarily Caucasians.
In an era where we strive for personalized medicine, understanding racial differences in MS may help us better treat African-American patients in the future.
KeywordsMultiple sclerosis African-Americans Progression Disease severity
Compliance with Ethical Standards
Conflict of Interest
Sara Klein declares no potential conflicts of interest.
Veronica P. Cipriani has received honoraria from Biogen Idec, Genentech, EMD Serono, and Sanofi Genzyme for educational or consulting activities. She has received honoraria for speaking for Genentech.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.Fabius CD, Thomas KS, Zhang T, Ogarek J, Shireman TI. Racial disparities in Medicaid home and community-based service utilization and expenditures among persons with multiple sclerosis. BMC Health Serv Res. 2018;18:773. https://doi.org/10.1186/s12913-018-3584-x.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.• Chi C, et al. Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genet. 2019;15(1):e1007808. https://doi.org/10.1371/journal.pgen.1007808 The authors report that African-Americans with European haplotype MS-associated alleles conferred three times the risk of MS than those on the African haplotype. CrossRefGoogle Scholar
- 16.• Langer-Gould A, Lucus R, Xiang AH, et al. MS Sunshine study: sun exposure but not vitamin D is associated with multiple sclerosis risk in Blacks and Hispanics. Nutrients. 2018;10:268. https://doi.org/10.3390/nu10030268 The authors report that only white patients had a lower risk of MS with higher serum vitamin D levels. However, lifetime sun exposure reduces the risk of MS in multiple racial/ethnic groups. CrossRefGoogle Scholar
- 17.Speeckaert MM, Speeckaert R, Van Geel N, et al. Vitamin D binding protein: a multifunctional protein of clinical importance. Adv Clin Chem. 2014;61:1–57.Google Scholar
- 24.•• Seraji-Bozorgzad N, Khan O, Cree B, et al. Cerebral grey matter atrophy is associated with the CSF IgG index in African American with multiple sclerosis. J Neuroimaging. 2017;27:476–80. https://doi.org/10.1111/jon.12435 The authors report that African-American patients have a strong inverse correlation between gray matter volume and CSF IgG index, compared with Caucasian patients. This supports the role of the humoral immune system in mediating MS pathology in African-American patients. CrossRefGoogle Scholar
- 25.• Caldito NG, Saidha S, Sotirchos ES, et al. Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study. Brain. 2018;141(11):3115–29. https://doi.org/10.1093/brain/awy245 This study reports an accelerated rate of neurodegeneration as seen in ganglion cell inner plexiform layer and brain atrophy rates in African-Americans. CrossRefGoogle Scholar
- 26.• Al-Kawaz EM, Morris E, Perumal JS, et al. Differential impact of multiple sclerosis on cortical and deep gray matter structures in African Americans and Caucasian Americans. J Neuroimaging. 2017;27:333–8. https://doi.org/10.1111/jon.12393 The authors reported race-related differences in MS brain atrophy patterns. African-American patients had cortical atrophy as compared with Caucasian patients, who had reduced thalamic volumes. CrossRefGoogle Scholar
- 28.• Lichtman-Mikol S, et al. Racial differences in retinal neurodegeneration as a surrogate marker for cortical atrophy in multiple sclerosis. Mult Scler Relat Disord. 2019;31:141–7. https://doi.org/10.1016/j.msard.2019.04.001 This study showed that ganglion cell inner plexiform layer thickness is a sensitive biomarker to predict brain atrophy and clinical disability in Caucasian patients, but not in African-American patients. CrossRefGoogle Scholar
- 30.Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol. 2011;68(4):464–8. https://doi.org/10.1001/archneurol.2011.45.CrossRefPubMedGoogle Scholar
- 32.Cree BA, Han J, Pradhan A, Masterman D, Williams MJ. OPERA I/II: efficacy in African-descended patients. Poster Session presented at the 34th ECTRIMS conference; 2018 Oct 10–12; Berlin, Germany.Google Scholar